<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02641522</url>
  </required_header>
  <id_info>
    <org_study_id>EMU-002</org_study_id>
    <nct_id>NCT02641522</nct_id>
  </id_info>
  <brief_title>Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes</brief_title>
  <official_title>Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carla Greenbaum, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Benaroya Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of siltuximab on immune cell functions
      in patients with Type 1 diabetes (T1D).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label (all people know the identity of the intervention), single center,
      non-randomized (patients are not assigned by chance to treatment groups), Mechanistic Study
      (a study that focuses on the biologic activity of the drug, rather than on disease
      treatment). Up to 10 patients with Type 1 diabetes (T1D) will be enrolled in the study.
      Participants will receive a single dose of siltuximab and blood samples will be obtained a
      total of 6 times until 12 weeks after dosing. Cells will be isolated from the blood samples
      and used to measure specific activities of cells in the immune system. Safety evaluations for
      adverse events, clinical laboratory tests, vital signs, and physical examination will be
      performed throughout the study. The end of study is the date of the last assessment for the
      last patient.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 8, 2016</start_date>
  <completion_date type="Actual">March 16, 2017</completion_date>
  <primary_completion_date type="Actual">March 16, 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in IL-6 Stimulated Intracellular p-STAT3 at Week 12</measure>
    <time_frame>0-to-12 weeks</time_frame>
    <description>Change in IL-6 stimulated intracellular p-STAT3 between Week 12 and baseline</description>
  </primary_outcome>
  <other_outcome>
    <measure>Adverse Event Monitoring</measure>
    <time_frame>0-to-12 weeks</time_frame>
    <description>Monitor adverse events associated with siltuximab treatment. All AE related to study drug will be tabulated along with their grade.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Post-Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single infusion of siltuximab (11 mg/kg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Siltuximab</intervention_name>
    <description>Single infusion of siltuximab (11 mg/kg)</description>
    <arm_group_label>Post-Infusion</arm_group_label>
    <other_name>Sylvant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Positive for at least one diabetes-related autoantibody any time since diagnosis,
             including by not limited to: Glutamate decarboxylase (GAD-65) Insulin, if obtained
             within 10 days of the onset of exogenous insulin therapy; IA-2; ZnT8

          2. Peak stimulated C-peptide level ≥ 0.1 pmol/mL following a mixed meal tolerance test
             (MMTT) conducted within 60 days of enrollment

          3. Females of child-bearing potential must be willing to use effective birth control and
             refrain from donating eggs for the purposes of assisted reproduction for duration of
             study.

          4. A woman of childbearing potential must have a negative serum (β-human chorionic
             gonadotropin [β-hCG]) or urine pregnancy test at screening and prior to dosing.

          5. During the study, and for 3 months after receiving the study agent, a woman must agree
             to not donate eggs (ova, oocytes) for the purposes of assisted reproduction.

          6. Willing and able to give informed consent for participation.

        Exclusion Criteria:

          1. History of severe reaction or anaphylaxis to human, humanized or murine monoclonal
             antibodies;

          2. History of malignancy or serious uncontrolled cardiovascular disease or hypertension,
             nervous system, pulmonary, renal, or gastrointestinal disease, or significant
             dyslipidemia despite therapy;

          3. Any history of recent (within 3 months) serious bacterial, viral, fungal, or other
             opportunistic infections;

          4. History or serologic evidence of current or past HIV, Hepatitis B, or Hepatitis C;

          5. Positive QuantiFERON or PPD TB test, history of tuberculosis, or active TB infection;

          6. Active infection with EBV ;

          7. Active infection with CMV;

          8. Diagnosis of liver disease or elevated hepatic enzymes, confirmed by repeat tests, as
             defined by ALT, AST, or both &gt; 1.5 x the upper limit of age-determined normal (ULN) or
             total bilirubin &gt; ULN;

          9. Any of the following hematologic abnormalities, confirmed by repeat tests:

               -  White blood count &lt;3,000/μL or &gt;14,000/μL

               -  Lymphocyte count &lt;500/μL

               -  Platelet count &lt;150,000 /μL

               -  Hemoglobin &lt;8.5 g/dL or &gt; or = to 17 g/dL

               -  Neutrophil count &lt;2,000 cells/μL

         10. Females who are pregnant or lactating;

         11. Receipt of live vaccine (e.g. varicella, measles, mumps, rubella, cold-attenuated
             intranasal influenza vaccine, bacillus Calmette-Guérin, and small pox) in the 6 weeks
             before treatment;

         12. Receipt of non-live vaccine in the 4 weeks before treatment;

         13. Any medical or psychological condition that in the opinion of the Sponsor Investigator
             would interfere with the safe completion of the trial;

         14. Receipt of an investigational drug (including investigational vaccines) or used an
             invasive investigational medical device within 3 months or 5 half-lives before
             enrollment or is currently enrolled in the treatment stage of an investigational
             study;

         15. Receipt of any immune-modulating biologic drug within 3 months of enrolling in the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carla Greenbaum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Benaroya Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Benaroya Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>December 23, 2015</study_first_submitted>
  <study_first_submitted_qc>December 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2015</study_first_posted>
  <results_first_submitted>March 1, 2018</results_first_submitted>
  <results_first_submitted_qc>March 1, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 9, 2018</results_first_posted>
  <last_update_submitted>October 5, 2018</last_update_submitted>
  <last_update_submitted_qc>October 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Benaroya Research Institute</investigator_affiliation>
    <investigator_full_name>Carla Greenbaum, MD</investigator_full_name>
    <investigator_title>Director, Diabetes Program</investigator_title>
  </responsible_party>
  <keyword>T1D</keyword>
  <keyword>Type 1 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Siltuximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 23, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT02641522/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Siltuximab</title>
          <description>Single infusion of siltuximab (11 mg/kg)
Siltuximab: Single infusion of siltuximab (11 mg/kg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Siltuximab</title>
          <description>Single infusion of siltuximab (11 mg/kg)
Siltuximab: Single infusion of siltuximab (11 mg/kg)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.1" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in IL-6 Stimulated Intracellular p-STAT3 at Week 12</title>
        <description>Change in IL-6 stimulated intracellular p-STAT3 between Week 12 and baseline</description>
        <time_frame>0-to-12 weeks</time_frame>
        <population>1 participant was excluded from analysis because of technical problems with processing samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Siltuximab</title>
            <description>Single infusion of siltuximab (11 mg/kg)
Siltuximab: Single infusion of siltuximab (11 mg/kg)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in IL-6 Stimulated Intracellular p-STAT3 at Week 12</title>
          <description>Change in IL-6 stimulated intracellular p-STAT3 between Week 12 and baseline</description>
          <population>1 participant was excluded from analysis because of technical problems with processing samples.</population>
          <units>Percent change from Baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.31" spread="15.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adverse Event Monitoring</title>
        <description>Monitor adverse events associated with siltuximab treatment. All AE related to study drug will be tabulated along with their grade.</description>
        <time_frame>0-to-12 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>0-to-12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Siltuximab</title>
          <description>Single infusion of siltuximab (11 mg/kg)
Siltuximab: Single infusion of siltuximab (11 mg/kg)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Nuetrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other - chalazion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Nuetrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sarah Robinson/ Administrative Assistant</name_or_title>
      <organization>Benaroya Research Institute</organization>
      <phone>(206) 342-6931</phone>
      <email>diabetes@benaroyaresearch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

